乳腺癌患者HER-2胞外结构域的临床价值

Serum HER-2 extracellular domain for breast cancer patients

目的探讨乳腺癌患者血清人类表皮生长因子受体2(HER-2)胞外结构域(ECD)的临床价值。方法选取乳腺癌患者93例、良性乳腺病患者40例及健康女性(正常对照组)55名,采用化学发光法定量检测所有对象血清HER-2 ECD水平,并分析乳腺癌患者血清HER-2 ECD水平与癌组织HER-2表达状态的一致性、血清HER-2 ECD与乳腺癌临床病理特征的关系及其对乳腺癌的诊疗效能。结果乳腺癌组血清HER-2 ECD水平[16.00(12.30,20.10)ng/mL]明显高于良性乳腺病组[6.05(4.85,7.95)ng/mL,P<0.05]和正常对照组[5.30(4.00,6.80)ng/mL,P<0.05]。乳腺癌患者癌组织HER-2表达阳性者的血清HER-2 ECD阳性率为73.08%,血清HER-2 ECD与癌组织HER-2表达的一致性较好。不同组织学分级、有无淋巴结转移及不同临床分期的乳腺癌患者血清HER-2 ECD水平差异有统计学意义(P<0.05)。结论乳腺癌患者血清HER-2 ECD与乳腺癌的临床特征关系密切,有望成为早期诊断乳腺癌、监测疗效、判断预后的重要指标之一。

ObjectiveTo investigate the role of serum human epidermal growth factor receptor 2（HER-2）extracellular domain（ECD）in breast cancer patients. MethodsA total of 93 breast cancer patients,40 benign breast disease patients and 55 healthy females were enrolled,and serum HER-2 ECD levels were determined by chemiluminescence. The consistency between serum HER-2 ECD level and the expression of tissue HER-2,the relation between serum HER-2 ECD and clinical pathological characteristics,and the ef？cacy in diagnosing breast cancer were analyzed. ResultsThe level of serum HER-2 ECD in breast cancer group [16.00（12.30,20.10）ng/mL] was higher than those in benign breast disease group [6.05（4.85,7.95）ng/mL,P〈0.05] and healthy control group [5.30（4.00,6.80）ng/mL,P〈0.05]. The positive rate of serum HER-2 ECD in breast cancer patients with tissue HER-2 expression positive was 73.08%,and the consistency between serum HER-2 ECD and tissue HER-2 expression was good. The difference of serum HER-2 ECD levels with different histological grades,lymph node metastasis or not and different clinical stages had statistical significance（P〈0.05）. ConclusionsSerum HER-2 ECD is related to the clinical characteristics of breast cancer. So,it is expected to become a valuable laboratory parameter in diagnosing breast cancer in early stage,monitoring treatment ef？cacy and judging the prognosis of breast cancer patients.